Webinar: How Can You De-Risk Your CNS Drug Development Process

Sponsored by: Imanova

Focused on:

  • C N S
  • Molecular Imaging
  • Early Phase Trials

Date: 23 May

185

Time: 4PM London/11AM New York

Why You Should Consider Imaging For The Decision-Making Data You Need in Early Phase Trials

The discovery and development of CNS drugs is an extremely challenging process requiring large resources, long timelines and high associated costs. The high risk of failure leads a considerable reluctance to commit appropriate resources to sustain the development of novel therapeutic mechanisms.

Over the last decade Positron Emission Tomography (PET) imaging has become a central component of the CNS drug development process, enabling decision making in Phase I studies, where early discharge of risk provides increased confidence to progress a candidate to more costly later phase testing at the right dose level or alternatively to kill a compound through failure to meet key criteria.

Positron Emission Tomography (PET) imaging is particularly well suited to the evaluation of the so called “three pillars” of drug survival, namely: tissue exposure, target engagement and pharmacological activity.

This webinar showcases the latest advances in Positron Emission Tomography (PET) imaging and how they provide quantitative information on the “three pillars” for decision-making on the critical path of CNS drug development.

Register for this webinar and understand how PET imaging can improve the drug development process.

Presented by

Roger Gunn,

Chief Scientific Officer

Roger Gunn is Chief Scientific Officer at Imanova, Professor of Molecular Neuroimaging in the Division of Brain Sciences at Imperial College London and Visiting Professor in the Department of Biomedical Engineering at the University of Oxford. He is an applied mathematician who has held positions in academia and industry in the UK and North America.

He is a world-leading expert in imaging sciences and their application to disease understanding and translational drug development. He has authored or coauthored over 150 peer reviewed publications in the field of imaging and has H Index > 50.

Roger’s publications on PubMed

Eugenii (Ilan) Rabiner,

Chief Medical Officer, Head of Imaging Applications

Dr Ilan Rabiner is Head of Imaging Applications & Chief Medical Officer at Imanova and Reader in Molecular NeuroImaging, Centre for Neuroimaging Sciences, IoPPN, King’s College, London, UK.

In 2012 was appointed as Reader in Molecular Neuroimaging at the Centre for Neuroimaging Sciences, in the Institute of Psychiatry, Kings College, London. Research interests focus on the application of molecular imaging to the investigation of neurochemistry and psychopharmacology and in particular to CNS drug development.

Ilan’s publications on PubMed

Key Learning Objectives

  • Understand how to provide decision-making data so you can significantly de-risk your CNS drug development during Phase I studies
  • Learn how Positron Emission Tomography (PET) imaging can measure tissue exposure of novel drugs, target engagement of novel drugs and pharmacological activity of novel drugs

Audience

  • Director/ VP of Clinical Research
  • Head of Clinical Development
  • Director of Clinical Studies
  • Director Discovery Medicine
  • Clinical Project Manager
  • Innovation Scientist
  • Senior/Principal Scientist
  • Translational Pharmacologist
  • Chief Medical Officer
  • Chief Scientific Officer
  • Research & Development
  • Translational Medicine
  • VP of Biomarkers/ Biomarker Development
  • Neuroscience Research
  • Project Lead Clinical Pharmacology
  • Project Lead Translational Medicine
  • Project Lead Modelling and Simulations
  • Project Lead Early Clinical Development